Gain Therapeutics Inc’s recent filing unveils that its CFO and Interim CEO Mack Gene acquired Company’s shares for reported $14544.0 on Aug 09 ’24. In the deal valued at $1.01 per share,14,400 shares were bought. As a result of this transaction, Mack Gene now holds 14,400 shares worth roughly $-33840.0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Islam Khalid bought 50,000 shares, generating $49,940 in total proceeds. Upon buying the shares at $1.00, the Executive Chairman now owns 50,000 shares.
Before that, RICHMAN ERIC I bought 17,000 shares. Gain Therapeutics Inc shares valued at $20,670 were divested by the Director at a price of $1.22 per share. As a result of the transaction, RICHMAN ERIC I now holds 289,629 shares, worth roughly $0.68 million.
A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in mid April with a ‘”an Outperform”‘ rating. BTIG Research began covering GANX with “Buy” recommendation on April 12, 2021.
Price Performance Review of GANX
On Monday, Gain Therapeutics Inc [NASDAQ:GANX] saw its stock jump 13.53% to $2.35. Over the last five days, the stock has gained 10.07%. Gain Therapeutics Inc shares have fallen nearly -28.02% since the year began. Nevertheless, the stocks have fallen -29.00% over the past one year. While a 52-week high of $5.33 was reached on 02/07/24, a 52-week low of $0.89 was recorded on 08/13/24. SMA at 50 days reached $1.43, while 200 days put it at $2.61.
Levels Of Support And Resistance For GANX Stock
The 24-hour chart illustrates a support level at 2.15, which if violated will result in even more drops to 1.94. On the upside, there is a resistance level at 2.46. A further resistance level may holdings at 2.56. The Relative Strength Index (RSI) on the 14-day chart is 71.23, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.22, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 1.22%. Stochastics %K at 85.85% indicates the stock is a selling.
How much short interest is there in Gain Therapeutics Inc?
A steep rise in short interest was recorded in Gain Therapeutics Inc stocks on 2024-09-30, growing by 98835.0 shares to a total of 0.65 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-30 was 0.56 million shares. There was a rise of 15.11%, which implies that there is a positive sentiment for the stock.
